Analysis of the effect of bezafibrate on the oxygen dissociation curve of human hemoglobin.
Analysis of the effects of a range of concentrations of the antihyperlipoproteinemia drug, bezafibrate, on the oxygen dissociation curve of dilute hemoglobin solutions indicates a 4:1 binding stoichiometry with a site binding constant of 434 mol-1 for deoxyhemoglobin. Analysis of the combined effects of a range of bezafibrate and 2,3-diphosphoglycerate (DPG) concentrations indicates that 2 of the 4 bezafibrate sites are in the vicinity of the DPG binding site, and competitive with DPG binding, and 2 of the sites are remote from the DPG binding site.
D019794:2,3-Diphosphoglycerate; D001629:Bezafibrate / Q000494:pharmacology*; D001665:Binding Sites; D001667:Binding, Competitive; D004163:Diphosphoglyceric Acids / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D010100:Oxygen / Q000378:metabolism*
D004163:Diphosphoglyceric Acids; D006454:Hemoglobins; D019794:2,3-Diphosphoglycerate; C100003:deoxyhemoglobin; D010100:Oxygen; D001629:Bezafibrate